Association of Janus kinase 2 (JAK2) polymorphisms with acute leukemia susceptibility

International Journal of Laboratory Hematology

Volumn 34, Issue 3, 2012, Pages 248-253

  Zhong, Y ^a   Wu, J ^a   Ma, R ^a   Cao, H ^a   Wang, Z ^a   Ding, J ^b   Cheng, L ^c   Feng, J ^a   Chen, B ^b  

^a JIANGSU CANCER HOSPITAL   (China)

^b MEDICAL SCHOOL OF SOUTHEAST UNIVERSITY   (China)

^c Southeast University   (China)

Author keywords

Acute leukemia; JAK2; Polymorphisms

Indexed keywords

GENOMIC DNA; JANUS KINASE 2;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ADULT; ARTICLE; CANCER RISK; CANCER SUSCEPTIBILITY; CASE CONTROL STUDY; CHINESE; CONTROLLED STUDY; DNA EXTRACTION; DNA POLYMORPHISM; EXON; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MISSENSE MUTATION; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; JANUS KINASE 2; LEUKEMIA; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84860233918     PISSN: 17515521     EISSN: 1751553X     Source Type: Journal    
DOI: 10.1111/j.1751-553X.2011.01386.x     Document Type: Article

References (26)

1. Argetsinger L.S., Campbell G.S., Yang X., Witthuhn B.A., Silvennoinen O., Ihle J.N. & Carter-Su C. (1993) Identification of JAK2 as a growth hormone receptor-associated tyrosine kinase. Cell 74, 237-244.
2. Baxter E.J., Scott L.M., Campbell P.J., East C., Fourouclas N., Swanton S., Vassiliou G.S., Bench A.J., Boyd E.M., Curtin N., Scott M.A., Erber W.N. & Green A.R. (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365, 1054-1061.
3. Bloomfield C.D. & Brunning R.D. (1985) The revised French-American-British classification of acute myeloid leukemia: is new better? Annals of Internal Medicine 103, 614-616.
4. Butcher C.M., Hahn U., To L.B., Gecz J., Wilkins E.J., Scott H.S., Bardy P.G. & D'Andrea R.J. (2008) Two novel JAK2 exon 12 mutations in JAK2V617F- negative polycythaemia vera patients. Leukemia 22, 870-873.
5. Damla O., Ashot H., Roland J., Tiina B., Bettina G., Ingrid P., Heinz G. & Robert K. (2009) A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms. Nature Genetics 41, 450-454.
6. Davey F.R., Castella A., Lauenstein K., Hubbell C. & Oates R.P. (1983) Prognostic significance of the revised French-American-British classification for acute lymphocytic leukaemia. Clinical Laboratory Haematology 4, 343-351.
7. Garofalo C. & Surmace E. (2006) Leptin and cancer. Journal of cellular physiology 207, 12-22.
8. Jaffe E.S., Harris N.L., Stein H. & Vardiman J.W. (2001) World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. IARC, Lyon, France.
9. James C., Ugo V., Le Couédic J.P., Staerk J., Delhommeau F., Lacout C., Garçon L., Raslova H., Berger R., Bennaceur-Griscelli A., Villeval J.L., Constantinescu S.N., Casadevall N. & Vainchenker W. (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434, 1144-1148.
10. Kralovics R., Passamonti F., Buser A.S., Teo S.S., Tiedt R., Passweg J.R., Tichelli A., Cazzola M. & Skoda R.C. (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. New England Journal of Medicine 352, 1779-1790.
11. Kratz C.P., Böll S., Kontny U., Schrappe M., Niemeyer C.M. & Stanulla M. (2006) Mutational screen reveals a novel JAK2 mutation, L611S, in a child with acute lymphoblastic leukemia. Leukemia 20, 381-383.
12. Lee J.W., Kim Y.G., Soung Y.H., Han K.J., Kim S.Y., Rhim H.S., Min W.S., Nam S.W., Park W.S., Lee J.Y., Yoo N.J. & Lee S.H. (2006) The JAK2 V617F mutation in de novo acute myelogenous leukemias. Oncogene 25, 1434-1436.
13. Leonard W.J., Imada K., Nakajima H., Puel A., Soldaini E. & John S. (1999) Signaling via the IL-2 and IL-7 receptors from the membrane to the nucleus. Cold Spring Harbor Symposia on Quantitation Biology 64, 417-424.
14. Levine R.L., Wadleigh M., Cools J., Ebert B.L., Wernig G., Huntly B.J., Boggon T.J., Wlodarska I., Clark J.J., Moore S., Adelsperger J., Koo S., Lee J.C., Gabriel S., Mercher T., D'Andrea A., Fröhling S., Döhner K., Marynen P., Vandenberghe P., Mesa R.A., Tefferi A., Griffin J.D., Eck M.J., Sellers W.R., Meyerson M., Golub T.R., Lee S.J. & Gilliland D.G. (2005) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7, 387-397.
15. Malinge S., Ben-Abdelali R., Settegrana C., Radford-Weiss I., Debre M., Beldjord K., Macintyre E.A., Villeval J.L., Vainchenker W., Berger R., Bernard O.A., Delabesse E. & Penard-Lacronique V. (2007) A novel activating JAK2 mutation in a down syndrome patient with B-cell acute lymphoblastic leukemia. Blood 109, 2202-2204.
16. Meydan N., Grunberger T., Dadi H., Shahar M., Arpaia E., Lapidot Z., Leeder J.S., Freedman M., Cohen A., Gazit A., Levitzki A. & Roifman C.M. (1996) Inhibition of acute lymphoblastic leukemia by a Jak-2 inhibitor. Nature 379, 645-648.
17. Neubauer H., Cumano A., Müller M., Wu H., Huffstadt U. & Pfeffer K. (1998) Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis. Cell 93, 397-409.
18. Pardanani A., Fridley B.L., Lasho T.L., Gary G. & Ayalew T. (2008) Host genetic variation contributes to phenotypic diversity in myeloproliferative disorders. Blood 111, 2785-2789.
19. Parganas E., Wang D., Stravopodis D., Topham D.J., Marine J.C., Teglund S., Vanin E.F., Bodner S., Colamonici O.R., Deursen J.M., Grosveld G. & Ihle J.N. (1998) Jak2 is essential for signaling through a variety of cytokine receptors. Cell 93, 385-395.
20. Poncz M., Solowiejczyk D., Harpel B., Mory Y., Schwartz E. & Surrey S. (1982) Construction of human gene libraries from small amounts of peripheral blood: analysis of beta-like globin genes. Hemoglobin 6, 27-36.
21. Sakai I. & Kraft A.S. (1997) The kinase domain of Jak2 mediates induction of bcl-2 and delays cell death in hematopoietic cells. Journal of Biological Chemistry 272, 12350-12358.
22. Schindler C. & Strehlow I. (2000) Cytokines and STAT signaling. Advances Pharmacology 47, 113-174.
23. Schnittger S., Bacher U., Kern W., Schröder M., Haferlach T. & Schoch C. (2006) Report on two novel nucleotide exchanges in the JAK2 pseudokinase domain: D620E and E627E. Leukemia 20, 2195-2197.
24. Steensma D.P., Dewald G.W., Lasho T.L., Powell H.L., McClure R.F., Levine R.L., Gilliland D.G. & Tefferi A. (2005) The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both ''atypical'' myeloproliferative disorders and the myelodysplastic syndrome. Blood 106, 1207-1209.
25. Zhang S.J., Li J.Y., Li W.D., Song J.H., Xu W. & Qiu H.X. (2007) The investigation of JAK2 mutation in Chinese myeloproliferative diseases-identification of a novel C616Y point mutation in a PV patient. Clinical Laboratory Haematology 29, 71-72.
26. Zhao R., Xing S., Li Z., Fu X., Li Q., Krantz S.B. & Zhao Z.J. (2005) Identification of an acquired JAK2 mutation in polycythemia vera. Journal of Biological Chemistry 280, 22788-22792.